{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T03:55:48Z","timestamp":1790654148372,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Jpn J Radiol"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>\n                      Boron neutron capture therapy (BNCT) dose planning conventionally uses a tumor-to-blood (T\/B) ratio derived from the tumor maximum standardized uptake value (SUVmax) of fluorine-18-labeled 4-borono-L-phenylalanine (\n                      <jats:sup>1<\/jats:sup>\n                      \u2078F-BPA) positron emission tomography (PET) (individual model). It remains unclear whether tumor SUVmax or individual model doses predict outcomes in accelerator-based BNCT for head and neck cancer (HNC). We investigated the correlation of\n                      <jats:sup>1<\/jats:sup>\n                      \u2078F-BPA PET SUVmax and individual model doses with treatment response.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>We retrospectively analyzed 30 patients with HNC treated with accelerator-based BNCT (2020\u20132021). The Kaplan\u2013Meier method was used for survival analysis. Dose parameters (Dmax, Dmin, and D80%) were calculated using the uniform model (T\/B\u2009=\u20092.5) and the individual model (T\/B\u2009=\u2009Tumor SUVmax\/Blood-pool SUV). Correlations between tumor SUVmax or dose parameters and best treatment response [complete response (CR) vs. non-CR] were evaluated using the Mann\u2013Whitney U test.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The objective response rate was 90%, and the CR rate was 50%. CR status strongly predicted superior 2\u00a0years overall survival, locoregional control, and progression-free survival (all\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05). However, no significant differences were observed between the CR and non-CR groups for tumor SUVmax, uniform model doses, or individual model doses (all\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&gt;\u20090.05).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      <jats:sup>1<\/jats:sup>\n                      \u2078F-BPA PET SUVmax and the conventional individual model did not demonstrate a statistically significant association with CR in patients with HNC after accelerator-based BNCT. These findings question the utility of tumor SUVmax-based dosimetry, suggesting that current models require refinement.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11604-026-02020-7","type":"journal-article","created":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T09:17:00Z","timestamp":1780391820000},"page":"1845-1853","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Correlation of tumor maximum standardized uptake value from 18F-BPA PET and boron neutron capture therapy tumor dose with treatment outcomes in head and neck cancer: a retrospective analysis"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0029-3467","authenticated-orcid":false,"given":"Yuki","family":"Yoshino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Takeno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teruhito","family":"Aihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayako","family":"Isohashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naonori","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasukazu","family":"Kanai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akinori","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai","family":"Nojiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Terada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Haginomori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiji","family":"Nihei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Ono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,2]]},"reference":[{"key":"2020_CR1","first-page":"1","volume":"36","author":"GL Locher","year":"1936","unstructured":"Locher GL. Biological effects and therapeutic possibilities of neutron. AJR Am J Roentgenol. 1936;36:1\u20133.","journal-title":"AJR Am J Roentgenol"},{"key":"2020_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2307\/3579742","volume":"151","author":"JA Coderre","year":"1999","unstructured":"Coderre JA, Morris GM. The radiation biology of boron neutron capture therapy. Radiat Res. 1999;151:1\u201318.","journal-title":"Radiat Res"},{"key":"2020_CR3","unstructured":"International Atomic Energy Agency. Advances in boron neutron capture therapy. Vienna: International Atomic Energy Agency; 2023."},{"key":"2020_CR4","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/S0140-6736(89)90567-9","volume":"2","author":"Y Mishima","year":"1989","unstructured":"Mishima Y, Honda C, Ichihashi M, Obara H, Hiratsuka J, Fukuda H, et al. Treatment of malignant melanoma by single thermal neutron capture therapy with melanoma-seeking 10B-compound. Lancet. 1989;2:388\u20139.","journal-title":"Lancet"},{"key":"2020_CR5","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1111\/cas.12602","volume":"106","author":"P Wongthai","year":"2015","unstructured":"Wongthai P, Hagiwara K, Miyoshi Y, Wiriyasermkul P, Wei L, Ohgaki R, et al. Boronophenylalanine, a boron delivery agent for boron neutron capture therapy, is transported by ATB0,+, LAT1 and LAT2. Cancer Sci. 2015;106:279\u201386.","journal-title":"Cancer Sci"},{"key":"2020_CR6","doi-asserted-by":"publisher","first-page":"21","DOI":"10.4251\/wjgo.v9.i1.21","volume":"9","author":"K Hayashi","year":"2017","unstructured":"Hayashi K, Anzai N. Novel therapeutic approaches targeting L-type amino acid transporters for cancer treatment. World J Gastrointest Oncol. 2017;9:21\u20139.","journal-title":"World J Gastrointest Oncol"},{"key":"2020_CR7","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.radonc.2020.11.001","volume":"155","author":"K Hirose","year":"2021","unstructured":"Hirose K, Konno A, Hiratsuka J, Yoshimoto S, Kato T, Ono K, et al. Boron neutron capture therapy using cyclotron-based epithermal neutron source and borofalan (10B) for recurrent or locally advanced head and neck cancer (JHN002): an open-label phase II trial. Radiother Oncol. 2021;155:182\u20137.","journal-title":"Radiother Oncol"},{"key":"2020_CR8","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1186\/s13014-021-01968-2","volume":"16","author":"N Hu","year":"2021","unstructured":"Hu N, Tanaka H, Kakino R, Yoshikawa S, Miyao M, Akita K, et al. Evaluation of a treatment planning system developed for clinical boron neutron capture therapy and validation against an independent Monte Carlo dose calculation system. Radiat Oncol. 2021;16:243.","journal-title":"Radiat Oncol"},{"key":"2020_CR9","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1186\/s12885-016-2913-x","volume":"16","author":"T Watanabe","year":"2016","unstructured":"Watanabe T, Hattori Y, Ohta Y, Ishimura M, Nakagawa Y, Sanada Y, et al. Comparison of the pharmacokinetics between L-BPA and L-FBPA using the same administration dose and protocol: a validation study for the theranostic approach using [18F]-L-FBPA positron emission tomography in boron neutron capture therapy. BMC Cancer. 2016;16:859.","journal-title":"BMC Cancer"},{"key":"2020_CR10","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s13550-014-0070-2","volume":"4","author":"K Hanaoka","year":"2014","unstructured":"Hanaoka K, Watabe T, Naka S, Kanai Y, Ikeda H, Horitsugi G, et al. FBPA PET in boron neutron capture therapy for cancer: prediction of (10)B concentration in the tumor and normal tissue in a rat xenograft model. EJNMMI Res. 2014;4:70.","journal-title":"EJNMMI Res"},{"key":"2020_CR11","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s12149-017-1172-5","volume":"31","author":"T Watabe","year":"2017","unstructured":"Watabe T, Hanaoka K, Naka S, Kanai Y, Ikeda H, Aoki M, et al. Practical calculation method to estimate the absolute boron concentration in tissues using 18F-FBPA PET. Ann Nucl Med. 2017;31:481\u20135.","journal-title":"Ann Nucl Med"},{"key":"2020_CR12","first-page":"1833","volume":"4","author":"Y Imahori","year":"1998","unstructured":"Imahori Y, Ueda S, Ohmori Y, Sakae K, Kusuki T, Kobayashi T, et al. Positron emission tomography-based boron neutron capture therapy using boronophenylalanine for high-grade gliomas: part II. Clin Cancer Res. 1998;4:1833\u201341.","journal-title":"Clin Cancer Res"},{"key":"2020_CR13","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1016\/j.apradiso.2004.05.059","volume":"61","author":"I Kato","year":"2004","unstructured":"Kato I, Ono K, Sakurai Y, Ohmae M, Maruhashi A, Imahori Y, et al. Effectiveness of BNCT for recurrent head and neck malignancies. Appl Radiat Isot. 2004;61:1069\u201373.","journal-title":"Appl Radiat Isot"},{"key":"2020_CR14","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1002\/hed.20418","volume":"28","author":"T Aihara","year":"2006","unstructured":"Aihara T, Hiratsuka J, Morita N, Uno M, Sakurai Y, Maruhashi A, et al. First clinical case of boron neutron capture therapy for head and neck malignancies using 18F-BPA PET. Head Neck. 2006;28:850\u20135.","journal-title":"Head Neck"},{"key":"2020_CR15","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1016\/j.ijrobp.2006.07.1373","volume":"66","author":"M Suzuki","year":"2006","unstructured":"Suzuki M, Sakurai Y, Nagata K, Kinashi Y, Masunaga S, Ono K, et al. Impact of intra-arterial administration of boron compounds on dose-volume histograms in boron neutron capture therapy for recurrent head-and-neck tumors. Int J Radiat Oncol Biol Phys. 2006;66:1523\u20137.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2020_CR16","first-page":"861","volume":"18","author":"Y Ariyoshi","year":"2007","unstructured":"Ariyoshi Y, Miyatake SI, Kimura Y, Shimahara T, Kawabata S, Nagata K, et al. Boron neutron capture therapy using epithermal neutrons for recurrent cancer in the oral cavity and cervical lymph node metastasis. Oncol Rep. 2007;18:861\u20136.","journal-title":"Oncol Rep"},{"key":"2020_CR17","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1093\/jrr\/rrt098","volume":"55","author":"M Suzuki","year":"2014","unstructured":"Suzuki M, Kato I, Aihara T, Hiratsuka J, Yoshimura K, Niimi M, et al. Boron neutron capture therapy outcomes for advanced or recurrent head and neck cancer. J Radiat Res. 2014;55:146\u201353.","journal-title":"J Radiat Res"},{"key":"2020_CR18","doi-asserted-by":"publisher","first-page":"277","DOI":"10.4172\/2161-119X.1000277","volume":"6","author":"T Aihara","year":"2016","unstructured":"Aihara T, Hiratsuka J, Fukumitsu N, Ishikawa H, Morita N, Kumada H, et al. Evaluation of fluorine-18-labeled boronophenylalanine-positron emission tomography imaging for the assessment of boron neutron capture therapy in patients with recurrent head and neck squamous cell carcinoma. Otolaryngol. 2016;6:277.","journal-title":"Otolaryngol"},{"key":"2020_CR19","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.ijrobp.2007.03.039","volume":"69","author":"L Kankaanranta","year":"2007","unstructured":"Kankaanranta L, Sepp\u00e4l\u00e4 T, Koivunoro H, Saarilahti K, Atula T, Collan J, et al. Boron neutron capture therapy in the treatment of locally recurred head and neck cancer. Int J Radiat Oncol Biol Phys. 2007;69:475\u201382.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2020_CR20","doi-asserted-by":"publisher","first-page":"e67","DOI":"10.1016\/j.ijrobp.2010.09.057","volume":"82","author":"L Kankaanranta","year":"2012","unstructured":"Kankaanranta L, Sepp\u00e4l\u00e4 T, Koivunoro H, Saarilahti K, Atula T, Collan J, et al. Boron neutron capture therapy in the treatment of locally recurred head-and-neck cancer: final analysis of a phase I\/II trial. Int J Radiat Oncol Biol Phys. 2012;82:e67-75.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2020_CR21","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.ijrobp.2015.11.010","volume":"95","author":"A Haapaniemi","year":"2016","unstructured":"Haapaniemi A, Kankaanranta L, Saat R, Koivunoro H, Saarilahti K, M\u00e4kitie A, et al. Boron neutron capture therapy in the treatment of recurrent laryngeal cancer. Int J Radiat Oncol Biol Phys. 2016;95:404\u201310.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2020_CR22","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.7250","volume":"13","author":"S Takeno","year":"2024","unstructured":"Takeno S, Yoshino Y, Aihara T, Higashino M, Kanai Y, Hu N, et al. Preliminary outcomes of boron neutron capture therapy for head and neck cancers as a treatment covered by public health insurance system in Japan: real-world experiences over a 2-year period. Cancer Med. 2024;13:e7250.","journal-title":"Cancer Med"},{"key":"2020_CR23","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/j.ijrobp.2024.03.041","volume":"120","author":"K Hirose","year":"2024","unstructured":"Hirose K, Sato M. Clinical results and prognostic factors in boron neutron capture therapy for recurrent squamous cell carcinoma of the head and neck under the Japan National Health Insurance System: a retrospective study of the initial 47 patients. Int J Radiat Oncol Biol Phys. 2024;120:796\u2013804.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2020_CR24","first-page":"433","volume":"34","author":"T Aihara","year":"2019","unstructured":"Aihara T, Hiratsuka J, Higashino M, Kawata R, Ono K. BNCT for head and neck cancer; current and future (in Japanese). Bio Clinica. 2019;34:433\u201340.","journal-title":"Bio Clinica"},{"key":"2020_CR25","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/0883-2889(91)90133-L","volume":"42","author":"K Ishiwata","year":"1991","unstructured":"Ishiwata K, Ido T, Mejia AA, Ichihashi M, Mishima Y. Synthesis and radiation dosimetry of 4-borono-2-[18F]fluoro-d,l-phenylalanine: a target compound for PET and boron neutron capture therapy. Int J Radiat Appl Instrum A. 1991;42:325\u20138.","journal-title":"Int J Radiat Appl Instrum A"},{"key":"2020_CR26","doi-asserted-by":"publisher","first-page":"186","DOI":"10.2307\/3578136","volume":"128","author":"J Hiratsuka","year":"1991","unstructured":"Hiratsuka J, Fukuda H, Kobayashi T, Karashima H, Yoshino K, Imajo Y, et al. The relative biological effectiveness of 10B-neutron capture therapy for early skin reaction in the hamster. Radiat Res. 1991;128:186\u201391.","journal-title":"Radiat Res"},{"key":"2020_CR27","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1016\/0360-3016(93)90533-2","volume":"27","author":"JA Coderre","year":"1993","unstructured":"Coderre JA, Makar MS, Micca PL, Nawrocky MM, Liu HB, Joel DD, et al. Derivations of relative biological effectiveness for the high-let radiations produced during boron neutron capture irradiations of the 9l rat gliosarcoma in vitro and in vivo. Int J Radiat Oncol Biol Phys. 1993;27:1121\u20139.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2020_CR28","doi-asserted-by":"publisher","first-page":"435","DOI":"10.2307\/3578693","volume":"138","author":"H Fukuda","year":"1994","unstructured":"Fukuda H, Hiratsuka J, Honda C, Kobayashi T, Yoshino K, Karashima H, et al. Boron neutron capture therapy of malignant melanoma using 10B-paraboronophenylalanine with special reference to evaluation of radiation dose and damage to the normal skin. Radiat Res. 1994;138:435\u201342.","journal-title":"Radiat Res"},{"key":"2020_CR29","doi-asserted-by":"publisher","first-page":"113","DOI":"10.2307\/3580083","volume":"152","author":"JA Coderre","year":"1999","unstructured":"Coderre JA, Morris GM, Kalef-Ezra J, Micca PL, Ma R, Youngs K, et al. The effects of boron neutron capture irradiation on oral mucosa: evaluation using a rat tongue model. Radiat Res. 1999;152:113\u20138.","journal-title":"Radiat Res"},{"key":"2020_CR30","unstructured":"Ono K. Two-step rate infusion of 4-borono-L-phenylalanine (BPA) solution in BPA-BNCT (Ono\u2019s method). In: Advances in boron neutron capture therapy. Vienna: International Atomic Energy Agency; 2023."}],"container-title":["Japanese Journal of Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11604-026-02020-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11604-026-02020-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11604-026-02020-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T03:08:53Z","timestamp":1790651333000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11604-026-02020-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,2]]},"references-count":30,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["2020"],"URL":"https:\/\/doi.org\/10.1007\/s11604-026-02020-7","relation":{},"ISSN":["1867-1071","1867-108X"],"issn-type":[{"value":"1867-1071","type":"print"},{"value":"1867-108X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,2]]},"assertion":[{"value":"13 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have influenced the work reported in this paper.","order":1,"name":"Ethics","label":"Competing Interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the ethics committee of our university (Study No. 2021\u2013172). The study was conducted in accordance with the principles of the Declaration of Helsinki (2024).","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent for the use of clinical data in research was obtained from all patients.","order":3,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}}]}}